Format

Send to

Choose Destination
Expert Rev Clin Immunol. 2014 Mar;10(3):349-52. doi: 10.1586/1744666X.2014.882771. Epub 2014 Feb 4.

Intravenous immunoglobulin in systemic capillary leak syndrome: a case report and review of literature.

Author information

1
Department of Clinical Medicine, Sapienza University of Rome, Clinical Immunology Unit, Rome, Italy.

Abstract

The systemic capillary leak syndrome (SCLS) is a rare condition characterized by unexplained episodic attacks of systemic capillary hyperpermeability accompanied by hypoalbuminemia, hemoconcentration and edema. Treatment of the acute phase is supportive, focusing on adequate fluid resuscitation. Many agents have been used to prevent acute attacks, including corticosteroids, β2-agonists (aminophylline, theophylline, or terbutaline), infliximab, thalidomide and intravenous immunoglobulin (IVIg). β2-agonists were the first-line maintenance therapy until a few years ago. In more recent years, IVIg became common first-line prophylactic therapy in most patients with benefits at the dose of 2 g/kg once a month. We report the case of a 49-year-old man with SCLS treated successfully with a lower dose of IVIg (1 g/kg monthly) in the maintenance phase. He presented no acute episodes in a follow-up of 28 months. We describe prophylactic treatments for SCLS in literature and compare our patient to another 18 who received IVIg in follow-up.

PMID:
24490827
DOI:
10.1586/1744666X.2014.882771
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center